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GLAtIRAmER ACEtAtE 40 mG/mL thREE tImES A WEEk fOR thE tREAtmENt 
Of RELAPSING fORmS Of mULtIPLE SCLEROSIS: POtENtIAL COSt BENEfItS 
Of A REGImEN WIth INfREqUENt INjECtIONS WhICh mAy mINImISE 
SWItChING tO thE NEWLy-INtRODUCED fIRSt-LINE AND SECOND-LINE 
DISEASE mODIfyING thERAPIES
Garcia Bujalance L1, Kelly M2, Blackney M2, Zeidman R2, Skroumpelos A3, Bijedic A1, 
Sánchez-de la Rosa R1, Plich A3
1Teva Pharmaceuticals, Madrid, Spain, 2Covance Market Access, London, UK, 3Teva 
Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
Objectives: The newly-introduced glatiramer acetate (GA; COPAXONE®) 40 mg/
ml three times a week maintains the known efficacy and safety of GA 20 mg/ml 
once-daily but requires around 200 fewer injections per year (60% fewer) for people 
treated for relapsing forms of multiple sclerosis (MS). An economic model with a 
five-year time horizon estimated the financial impact to the Spanish healthcare 
system of reduced switching from GA-based regimens to more expensive newly-
introduced first-line disease modifying therapies (DMTs) and the second-line 
DMTs. MethOds: The eligible population was based on 2014 Spanish MS inci-
dence rates, with the proportion receiving DMTs calculated using market research 
data. Medication costs were based on known Spanish prices, while treatment initia-
tion, administration and monitoring costs were calculated from published Spanish 
sources and Summary of Product Characteristics documentation. Switching rates 
and future treatment patterns were based on manufacturer’s projections. Results: 
An estimated 5,084 people with MS received GA 20 mg/ml once-daily in Spain in 
2014 (12.1% of those receiving DMTs) and were assumed to switch to more expen-
sive newly-introduced first-line and second-line DMTs at an annual rate of 8%. 
Assuming these people received GA 40 mg/ml three times a week instead, and – due 
to requiring fewer injections – switched at an annual rate of 5%, total expenditure 
on DMTs and related costs was reduced by between € 5.9 million and € 7.2 million 
annually, with savings totalling € 32.8 million over five years: a 21% reduction in total 
expenditure related to DMTs included in the model, compared with GA 20 mg/ml 
once-daily. Savings were primarily driven by lower acquisition costs of GA compared 
with other DMTs, and also from lower initiation, administration and monitoring 
requirements. cOnclusiOns: Introducing GA 40 mg/ml three times a week may 
limit switching from GA to more expensive newly-introduced first- and second-line 
DMTs, potentially generating cost savings.
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BUDGEt ImPACt Of PERAmPANEL fOR thE tREAtmENt Of PAtIENtS WIth 
PARtIAL-ONSEt SEIzURES (POS) IN RUSSIA
Tremblay G1, Patel V2, Tsong WH2, Forsythe A2, Moiseev A3, Belousov D4
1Eisai, Woodcliff Lake, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Eisai LLC, Moscow, Russia, 
4Center of Pharmacoeconomic Research LLC, Moscow, Russia
Objectives: The objective of this study was to estimate the incremental budget 
impact (BI) of utilizing perampanel to treat partial-onset seizures (POS) in patients 
who are 12 years of age and older in Russia. MethOds: The incremental BI was 
estimated by comparing the cost of POS seizures with and without perampanel. 
Direct (drugs, healthcare provider visits, emergency room visits, hospitalizations) 
and indirect (overall work impairment) costs were included. The model was devel-
oped from a societal perspective. The time horizon is five years. Costs are reported 
in rubles (RUB). Results: An estimated 351,582 patients ages 12 years and older 
are treated for POS in Russia each year. Approximately 53% are refractory (experi-
encing persistent seizures despite current treatment). The market share uptake of 
perampanel in POS patients is estimated to be 3%, 5%, 10%, 15% and 20%, in years 1 
to 5, respectively. During these five years, the adoption of perampanel is projected to 
increase overall costs by 305M, 510M, 1,022M, 1,537M and 2,055M RUB, respectively. 
Due to seizure reductions with perampanel, 27% of the drug cost increase (5,428M 
RUB) over 5 years is offset by the lower utilization of direct medical resources (RUB 
-25M) and lower overall work impairment (RUB -1,450M), yielding an overall BI of 
2.5% over 5 years. cOnclusiOns: With a budget impact of only 2.5% over a period of 
5 years and demonstrated efficacy benefits in refractory POS patients (63% median 
reduction in secondarily generalized seizures and 13% seizure freedom rate), per-
ampanel should be considered a valuable treatment.
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COSt OffSEtS ASSOCIAtED WIth REBIf USE IN fIRSt-LINE RRmS: AN 
ANALySIS BASED ON thE COChRANE COLLABORAtION REvIEW AND  
REAL-WORLD PERSIStENCE DAtA
Wong SL1, Fujii R1, Beckerman R2
1EMD Serono, Inc., Billerica, MA, USA, 2CBPartners, New York, NY, USA
Objectives: To project the number and costs of relapses and escalations to second-
line therapy over 2 years for subcutaneous (SC) interferon beta (IFNβ )-1a (Rebif®), 
intramuscular (IM) IFNβ -1a, IFNβ -1b, and glatiramer acetate (GA) in the treatment of 
first-line relapsing-remitting multiple sclerosis (RRMS) from the perspective of the 
UK National Health Service (NHS). MethOds: A four-state (initial therapy, alternate 
first-line therapy, second-line therapy [natalizumab], and discontinuation) Markov 
model was constructed to simulate a cohort of 1,000 newly-diagnosed RRMS patients. 
Transition probabilities were based on real-world persistence data from the NHS 
and a patient treatment flow study. Risk of relapse was linearly interpolated based 
on 2-year data from a Cochrane Review network meta-analysis. The cost of a relapse 
was sourced from the literature and inflated to 2014 GBP. Drug acquisition costs were 
sourced from the British National Formulary. Administration costs were sourced from 
a NICE costing template. One-way sensitivity analyses were performed to test the 
robustness of the model results. Results: Treatment with SC IFNβ -1a is projected 
to avoid 94, 7, and 7 additional relapses compared with IM IFNβ -1a, IFNβ -1b, and GA, 
respectively, resulting in cost savings of £279,460, £20,877, and £20,877 over 2 years 
in a hypothetical cohort of 1,000 newly-diagnosed RRMS patients. Treatment with 
corticosteroid pulse and plasmapheresis may help in acute attacks of NMO. Further 
well designed, adequately powered studies are required in this context.
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vARIAtION IN StAtE-LEvEL vS. NAtIONAL INCIDENCE IN RARE GENEtIC 
DISEASE: A mONtE CARLO SImULAtION tO ExAmINE SAmPLING vARIAtION 
AS A PRImARy ExPLANAtION IN CONGENItAL ADRENAL hyPERPLASIA
Alnafesah A, Rittenhouse B
MCPHS University, Boston, MA, USA
Objectives: The cost-effectiveness of CAH screening (a state-level policy) was 
assessed by Yoo and Grosse (2009) using national incidence (NATL). Incidence of 
rare genetic diseases often varies geographically, however, it is likely that some 
state variation is due to sampling error. This research assesses the extent of the 
sampling error explanation through a series of simulations. MethOds: We obtained 
actual state-level incidence (ASI) for the 50 US states plus DC for 2006. For the 
simulation we assumed that state equaled national incidence and constructed a 
Beta distribution with alpha parameter equaling predicted state cases, and Beta 
parameter equaling state births minus predicted cases. We then ran a Monte Carlo 
simulation of 1000 iterations and calculated the proportion of iterations for which 
the incidence draw was more extreme than the ASI (i.e. draw > ASI if ASI > NATL or 
draw < ASI if ASI < NATL). Small numbers of iterations more extreme than the ASI 
are consistent with the ASI not equaling NATL. Extreme was defined as less than 5% 
of draws in the simulation less than the ASI (if ASI< NATL) or greater than the ASI 
(if ASI > NATL). Results: ASI per 1000 births ranged from 0 to .343 (median, .038). 
There were 21 states with ASI < NATL (including 13 values of 0) and 25 states with 
ASI > NATL. Of the 46 states reporting ASI, 21 (47%) had an “extreme” ASI by our 
definition. cOnclusiOns: State incidence appears to be “extreme” vs the national 
average in a large number of states and, therefore, does not seem to be explained 
by sampling error alone. As a difference in incidence may affect cost-effectiveness, 
further exploration using ASIs instead of a national average may be beneficial for 
directing state-level screening policy.
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SOCIAL DEmOGRAPhIC ChARACtERIStICS AND DIRECt mEDICAL COStS fOR 
PAtIENtS WIth PARkINSON’S DISEASE IN kOREA : BIG DAtA ANALySIS fROm 
thE NAtIONAL hEALth INSURANCE CLAImS DAtASEt
Kwak M
Medtronic Korea, Seoul, South Korea
Objectives: The research is to analyze social demographic characteristics and 
health service use nature of Parkinson’s disease in Korea by using Korean National 
Health Insurance Claims dataset (HIRA-NPS 2013), which is one of the secondary 
sources of health and medical treatment provided by reimbursement authority, 
and to measure a direct medical costs of Parkinson’s disease. MethOds: Patients 
with primary or secondary disease code for Parkinson’s Disease according to Korean 
Standard Classification of Disease (KICD-10 code : G20) are selected from National 
Patients Sample Dataset. The characteristics of age, sex, length of stay for inpatients, 
the number of outpatient visit and medical cost were analyzed based on the patient 
dataset extracted. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was used for statistical 
analysis. Results: The number of patients with Parkinson’s disease for the analysis 
was 4,137, and that of claims cases for 12 months was 34,259. The average age of 
the patients was 71.6 years old and the female patients composed 60.11%, which 
was about 1.5 times that of the male patients. The prevalence rate of Parkinson’s 
disease per 1,000 populations was 3.54 in 2013. Based on 1-year claims dataset, 
outpatient visit days were 9.83 and inpatient hospitalization days were 25.3. The 
annual direct medical costs were USD 487 for an outpatient and USD 10,429 for an 
inpatient. cOnclusiOns: As the result, the Parkinson’s disease is the economic 
burden in aging society in Korea. The limitation that the sample data used for 
the research is smaller than the raw data should be considered. Therefore further 
analysis on Parkinson’s disease in aging society is needed.
PND16
fORECAStING thE PREvALENCE Of StAtUS EPILEPtICUS AND ItS SUBtyPES 
IN EUROPE, 2015–2024
Stuntz M
Deerfield Institute, New York, NY, USA
Objectives: To estimate the prevalence of status epilepticus (SE), refractory status 
epilepticus (RSE), and super-refractory status epilepticus (SRSE) in five major European 
Union (5EU) markets (France, Germany, Italy, Spain, and the United Kingdom) using 
an incidence-survival model. MethOds: Yearly survival data for each SE etiology 
(acute symptomatic, progressive symptomatic, remote symptomatic, and idiopathic/
cryptogenic) were extracted from published research. Incident cases were calculated 
for each etiology beginning with 1995, based on market-specific published rates. 
Applying the survival proportions and incidence estimates to the model for each 
etiology, we calculated an overall estimate of the prevalence of SE. RSE and SRSE 
prevalent cases were assessed as proportions of the total number of prevalent SE 
cases using published values. Results: We estimated the prevalence of SE to be 
18.4 cases per 10,000 population in the 5EU, resulting in 590,264 cases in 2015 and 
increasing to 603,951 in 2024. The calculated prevalence ranged from 17.2 cases per 
10,000 (Germany) to 19.7 cases per 10,000 (Italy). The prevalence of RSE in the 5EU was 
4.5 per 10,000, resulting in 145,205 cases in 2015, increasing to 148,572 in 2024. SRSE 
prevalence in the 5EU was 1.8 per 10,000, resulting in 59,027 cases in 2015, increas-
ing to 60,395 in 2024. cOnclusiOns: To our knowledge, this is the first attempt to 
calculate the prevalence of SE and its subtypes for all ages in Europe. Estimating the 
prevalence of SE, RSE, and SRSE using population-based epidemiological methods is 
challenging because of the variability of SE disease definitions and the unpredictable 
nature of mortality due to SE. Our incidence-survival model provides an alternative 
and effective method to assess the prevalent population. Considering the high costs 
associated with treatment and hospitalization of SE, RSE, and SRSE patients, these 
estimates are necessary to quantify the burden of disease in Europe.
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taken from the essential drug list and the database of drugs prices. Standard 
of treatment of CP developed by Ministry of Health of the Russian Federation 
was used for calculation of medical care costs. Costs of adverse events were 
calculated basing on Russian clinical guidelines and database of drugs prices. 
Disability pensions and disable child care were taken from the Russian Pension 
Fund database. The cost of orthopedic surgeries was calculated on the basis of RF 
Government program of state guarantees of free rendering to citizens of medi-
cal care. Results: Usage of AbobotulinumtoxinA treatment+standard therapy 
in whole population of SCP patients in Russia will result in 79,585 RUB/1,473 
$ economy compared with OnabotulinumtoxinA+standard therapy, 131,178 
RUB/2,429 $ economy compared with standard therapy per one patient for 2 
years. This cost reduction is mainly attributed to decrease of number of ortho-
pedic surgeries to the better efficacy of this BTA drug. cOnclusiOns: Inclusion 
of abobotulinumtoxinA+standard therapy appears to be a cost saving treatment 
option in the management of spastic cerebral palsy in the Russian Federation com-
pared with onabotulinumtoxinA+standard therapy and standard therapy solely.
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BUDGEt ImPACt ANALySIS fOR PEGINtERfERON BEtA-1A IN RELAPSING 
REmIttING mULtIPLE SCLEROSIS IN ItALy
Iannazzo S1, Santoni L2, Saleri C2, Puma E2, Vestri G2, Giuliani L1, Centonze D3,  
Canonico PL4
1SIHS Health Economics Consulting, Torino, Italy, 2Biogen, Milan, Italy, 3Università Tor Vergata, 
Rome, Italy, 4Università del Piemonte Orientale, Novara, Italy
Objectives: PEGIFN beta-1a is the first pegylated interferon beta-1a administered 
subcutaneously every two weeks, indicated for the therapy of relapsing remit-
ting multiple sclerosis (RRMS). The objective of this analysis was to estimate the 
potential economic impact following due of the introduction of PEGIFN beta-1a in 
Italy. MethOds: The analysis was conducted with a three-year time horizon with 
the support of a decision-analytic model adopting the perspective of the Italian 
National Healthcare Service (NHS). Healthcare costs sustained by the Italian NHS for 
the management of the RRMS population (drug treatment, monitoring, relapse man-
agement, adverse event management) were calculated over 3 years and compared 
for two scenarios: i) The current scenario where only interferon beta and glatiramer 
acetate are RRMS patients available and ii) An alternative scenario after the intro-
duction of PEGIFN beta-1a. The RRMS population was estimated to be approximately 
35,500, 37,500 and 39,500 patients at Year 1, 2 and 3 respectively, based on published 
epidemiology literature and market data. The efficacy of treatments was simulated 
as reduction of relapse rates and was derived from a mixed treatment comparison. 
Unit costs were based on Italian 2015 prices and tariffs, and the published literature. 
A one-way sensitivity analysis was developed. Results: According to current price 
and reimbursement conditions established by the Italian NHS, the introduction 
of PEGIFNb-1a will result in cost savings. This model found that PEGIFN beta- 1a 
would provide in related of treating RRMS patients an estimated annual costs of 
€ 318,800,000, € 336,100,000 and € 353,600,000 in Year 1, 2, and 3 respectively compared 
to the costs of the current scenario of € 319,200,000, € 337,200,00 and € 355,200,000 
in Year 1, 2, and 3, respectively. The cumulative budget reduction over the three 
year period was € 3,100,000 (an approximate 0.3% savings). cOnclusiOns: The 
adoption of PEGIFN beta-1a for the treatment of RRMS is economically sustainable 
by the Italian NHS.
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thE BUDGEt ImPACt ANALySIS Of ADjUNCtIvE thERAPy fOR PAtIENtS 
WIth PARtIAL EPILEPSy
Pyadushkina E1, Avxentyeva M1, Frolov M2
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2Volgograd State Medical University, Volgograd, Russia
bAckgROund: Epileptic seizures are associated with significantly impaired quality 
life, excessive healthcare resource use and thus high costs. According to published 
sources based on clinical data new anti-epileptic add-on therapy options for refrac-
tory patients with partial-onset seizures with or without secondary generalisation, 
such as lacosamide and perampanel, has achieved greater efficacy by responder 
rates (better control of the seizures) and seizure freedom than placebo being equally 
effective between each other. Objectives: to estimate the budgetary impact of the 
introduction of 2 types of adjunctive treatment in adult patients with refractory 
partial epilepsy (RPE) - lacosamide and perampanel added to standard treatment, 
and to forecast this impact over the following three years in Kaliningrad region of 
Russian Federation. MethOds: The budget impact model has been developed for 
the Russian Federation regions. Efficacy data used to assess the resource consump-
tion was taken from randomized clinical trials and meta-analysis. The demographic 
parameters and the partial epilepsy incidence were calculated based on the official 
statistic surveillance system data for the regions. Resource use was estimated by 
expert survey. Drug and other medical costs were calculated on the basis of regis-
tered vital and essential drug list prices and regional tariffs. Results: Introduction 
of lacosamide to clinical practice (as add-on anti-epileptic treatment) compared to 
perampanel with equal market shares of 10%, 20% and 30% leads to average budget 
savings of healthcare system in Kaliningrad region, which amounted to: € 27 081.25 
in first year, € 43 746.63 in the second year, € 78 119.00 in the third year, for treat-
ing 131, 140 and 149 patients with RPE, respectively. cOnclusiOns: The analysis 
showed that introduction of adjunctive therapy with lacosamide in the market for 
the treatment of patients with PRE compared to perampanel could save budget 
funds by reducing drug costs in Russian Federation regions.
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BUDGEt ImPACt ANALySIS Of PRAmIPExOLE ExtENDED RELEASE 
mONOthERAPy IN EARLy PARkINSON’S DISEASE
Belousov D1, Afanasieva E2
1Center of Pharmacoeconomic Research LLC, Moscow, Russia, 2LLC «Center of Pharmacoeconomic 
Research», Moscow, Russia
SC IFNβ -1a is projected to avoid 28, 10, and 10 additional escalations to second-line 
therapy compared with IM IFNβ -1a, IFNβ -1b, and GA, respectively, resulting in cost sav-
ings of £685,391, £231,021, and £231,021. Results were most sensitive to each therapy’s 
risk of relapse at 2 years. cOnclusiOns: Among newly-diagnosed RRMS patients, 
treatment with SC IFNβ -1a is projected to avoid more relapses and escalations to 
second-line therapy compared with IM IFNβ -1a, IFNβ -1b, and GA over 2 years. These 
projected cost offsets within the UK may be applicable to other payer environments.
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REAL-WORLD DAtA AND BUDGEt ImPACt ANALySIS fOR INCOBOtULINUm 
tOxIN A AND ONABOtULINUm tOxIN A fOR UPPER LImB POSt-StROkE 
SPAStICIty At A Uk CENtRE
Robertson A1, Datta P1, Kusel J2, Page S3, Soon J4
1Mid Yorkshire Hospitals NHS Trust, West Yorkshire, UK, 2Costello Medical Consulting Ltd, 
Cambridge, UK, 3Costello Medical Consulting Ltd., Cambridge, UK, 4Merz Pharma UK Ltd., Elstree, 
UK
Objectives: Botulinum toxins (BT) are a valuable treatment option for patients 
with post-stroke upper-limb spasticity (PS-ULS), which affects 33,000 patients in 
the UK. Xeomin (incobotulinum toxin A) and Botox (onabotulinum toxin A) are 
two BTs licensed for the treatment of PS-ULS. The treatment costs for Xeomin and 
Botox will depend on their real-world usage. MethOds: Dosing data were col-
lected for patients switching from Botox to Xeomin treatment between 2007–2012 
from the Mid-Yorkshire Hospitals Trust (MYHT) UK (comprised of 3 centres). The 
dose of each BT received per limb at each visit was extracted from the dataset for 
7 visits (the 3 visits before and 4 visits after switching). List prices from the British 
National Formulary for different vial sizes were applied to these data to generate a 
simple budget impact model. Results: 89 patients (127 limbs) were identified who 
switched treatment from Botox to Xeomin, of which 49 patients (54 limbs) fulfilled 
study criteria. The average dose of Xeomin was 147.2 units per limb and Botox was 
156.9 units per limb. Due to the lower list price of Xeomin and the comparable 
dosing frequency between Botox and Xeomin (average time between injections 
was 154 days for Botox and 156 days for Xeomin), switching resulted in an aver-
age cost-saving of £26 per limb, per visit. This represented an estimated overall 
annual saving of £3,263. Accounting for sharing of vials reduced the estimated 
saving slightly (£3,166 overall). The real-world saving made by MYHT was greater 
than this as this analysis included upper-limb spasticity only, therefore a number 
of limbs did not fit study criteria and were not included in the estimated annual 
savings. cOnclusiOns: Real-world dosing for Xeomin and Botox was comparable. 
Based on the lower list price of Xeomin, this indicated potential cost savings for 
switching from Botox to Xeomin.
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COSt OffSEt ANALySIS Of INtERfERON BEtA DISEASE mODIfyING 
thERAPIES IN RELAPSING-REmIttING mULtIPLE SCLEROSIS
Beckerman R1, Locklear JC2, Smith NJ3, Phillips AL2
1Maple Health Group, LLC, New York, NY, USA, 2EMD Serono, Inc., Rockland, MA, USA, 
3CBPartners, New York, NY, USA
Objectives: To compare direct medical costs for patients with relapsing-remit-
ting multiple sclerosis (RRMS) treated with subcutaneous (sc) IFNβ 1a 44mcg three 
times weekly (TIW) versus other interferon-beta (IFNβ ) therapies across endpoints 
comprising the “no evidence of disease activity” (NEDA) measure. MethOds: A 
decision-analytic model was developed using comparative efficacy data sourced 
from a network meta-analysis (NMA) of IFNβ therapies: scIFNβ 1a 44mcg TIW, 
scIFNβ 1b 250mcg every other day, intramuscular (im) IFNβ 1a 30mcg once weekly, 
and pegylated (peg) IFNβ 1a 125mcg every two weeks. The number of patients experi-
encing NEDA-related endpoints (relapse, new MRI activity, or disability progression) 
for each therapy was determined using risk ratios derived from odds ratios (ORs) vs. 
placebo (pairwise analysis) or vs. other IFNβ therapies (NMA analysis). The model 
followed 1,000 patients with RRMS over 2 years. Costs were sourced from the litera-
ture. One-way sensitivity analyses (OWSAs) were performed to test the robustness 
of the results. Results: Only medical costs were assessed, thus observed cost-
offsets meant fewer patients experienced NEDA-related endpoints. For scIFNβ 1a 
44mcg vs. pegIFNβ 1a, results from the pairwise analysis projected cost-offsets of 
$893,652 (relapse) and $252,219 (MRI); results from the NMA also projected cost-
offsets of $578,174 (relapse), $15,628 (disability), and $105,667 (MRI). For scIFNβ 1a 
44mcg vs. imIFNβ 1a, results from the pairwise analysis projected cost-offsets of 
$755,737 (relapse) and $239,926 (MRI); results from the NMA also projected cost-
offsets of $525,511 (relapse), $118,716 (disability), and $110,435 (MRI). For scIFNβ 1a 
44mcg vs. scIFNβ 1b, results from the pairwise analysis projected cost-offsets of 
$84,826 (relapse) and $32,435 (disability); results from the NMA also projected a 
cost-offset of $35,948 (disability). OWSAs confirmed substantial cost-offsets for the 
comparisons examined. cOnclusiOns: The results of this decision-analytic model 
suggests that scIFNβ 1a 44mcg provides substantial cost-offsets versus other IFNβ 
treatments across NEDA-related endpoints.
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BUDGEt ImPACt ANALySIS Of BOtULINUm tOxIN tyPE A tREAtmENt fOR 
CEREBRAL PALSy IN thE RUSSIAN fEDERAtION
Yagudina R, Kulikov A, Ugrekhelidze D
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To conduct budget impact analysis of abobotulinumtoxinA+standard 
therapy, onabotulinumtoxinA+standard therapy and standard therapy solely 
in patients with spastic cerebral palsy (SCP) in Russia for 2-year period. Total 
number of patients with spastic cerebral palsy in Russia is 55 899. MethOds: 
A budget impact model was developed in Excel 2013 to simulate the costs of 
spastic cerebral palsy therapy in the Russian Federation. The following costs 
were taken into account: the costs of pharmacotherapy, inpatient and outpatient, 
sanatorium-resort care, costs of adverse events, casting, orthopedic surgeons, 
disability pensions, disable child care benefit. Costs of pharmacotherapy were 
